Danaher Stock Forecast for 2022 - 2025 - 2030
Updated on 05/24/2022
The average target price for Danaher's stock set by seven renowned analysts in recent months is $335.00, representing a potential upside of approximately 32.94% from its last closing price if met by 2023. This estimation is based on a high estimate of $375.00 and a low estimate of $200.00. Although you may not be interested in DHR stock, you should still be aware of its competitors.
32.94% Upside
Danaher Fair Value Forecast for 2022 - 2025 - 2030
In the last three years, Danaher's Fair Value has seen significant growth, surging from $136.32 to $303.11 – an increase of 122.35%. In the next year, analysts predict that Fair Value will jump to $313.97 – up 3.58% from the current level. Looking ahead to nine years, experts forecast that Fair Value will grow by 127.36%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| AVGO Stock Forecast | Broadcom | Outperform |
7
|
$524.20 | $687.47 | 33.54% | 25 |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
7
|
$113.77 | $141.24 | 23.06% | 19 |
| BMY Stock Forecast | Bristol-Myers Squibb | Outperform |
8
|
$77.13 | $76.69 | 1.13% | 16 |
| AMGN Stock Forecast | Amgen | Hold |
6
|
$251.89 | $246.46 | -0.75% | 13 |
| MMM Stock Forecast | 3M | Hold |
5
|
$145.75 | $188.41 | 9.98% | 17 |
Danaher Revenue Forecast for 2022 - 2025 - 2030
In the last three years, Danaher's Revenue has seen significant growth, surging from $17.05B to $29.45B – an increase of 72.76%. In the next year, analysts predict that Revenue will jump to $30.82B – up 4.65% from the current level. Looking ahead to nine years, experts forecast that Revenue will grow by 79.83%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| GE Stock Forecast | General Electric | Outperform |
2
|
$74.52 | $121.44 | 43.59% | 13 |
| BDX Stock Forecast | Becton, Dickinson and | Outperform |
5
|
$257.45 | $270.20 | 10.7% | 3 |
| BAYN Stock Forecast | Bayer | Outperform |
5
|
63.29€ | 67.79€ | 20.08% | 14 |
Danaher Dividend per Share Forecast for 2022 - 2025 - 2030
In the past three years, Danaher's DPS has seen a relatively significant increase, rising from $0.64 to $0.84. This represents a growth of 31.25%. Analysts predict that Danaher's DPS will increase moderately in the upcoming year, reaching $1.05. This would represent an increase of 25%. Over the next nine years, experts predict that Danaher's DPS will grow at a rate of 252.77%
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| EW Stock Forecast | Edwards Lifesciences | Outperform |
5
|
$94.54 | $127.85 | 37.51% | 19 |
| BSX Stock Forecast | Boston Scientific | Outperform |
4
|
$40.15 | $49.85 | 24.53% | 23 |
| ETN Stock Forecast | Eaton | Outperform |
4
|
$133.83 | $182.50 | 30.76% | 20 |
Danaher Free Cash Flow Forecast for 2022 - 2025 - 2030
In three years, Free Cash Flow for Danaher has grown by a whopping 109.84%, going from $3.37B to $7.06B. In the coming year, analysts are expecting a small increase in Free Cash Flow, predicting it will reach $7.55B – an increase of 6.92%. Over the next nine years, experts anticipate that Free Cash Flow growth for Danaher will be 128.14%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| F Stock Forecast | Ford Motor | Hold |
6
|
$12.42 | $21.82 | 44.93% | 16 |
| EMR Stock Forecast | Emerson Electric | Outperform |
4
|
$83.89 | $110.43 | 31.12% | 10 |
| DOW Stock Forecast | Dow | Outperform |
3
|
$67.07 | $64.10 | 10.33% | 11 |
Danaher Net Income Forecast for 2022 - 2025 - 2030
Danaher's Net Income has seen astonishing growth in the last three years, going from $2.65B to $6.43B – a gain of 142.67% In the next year, analysts believe that Net Income will reach a reasonable $7.70B – an increase of 19.74% For the next nine years, the forecast is for Net Income to grow by 99.85%
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| 6501 Stock Forecast | Hitachi | Buy |
4
|
¥6.40k | ¥0.00 | 24.98% | 0 |
| ECL Stock Forecast | Ecolab | Outperform |
4
|
$158.40 | $204.59 | 21.84% | 10 |
| A Stock Forecast | Agilent Technologies | Outperform |
7
|
$124.41 | $172.40 | 28.61% | 2 |
Danaher EBITDA Forecast for 2022 - 2025 - 2030
Danaher's EBITDA has seen major growth over the last three years, jumping from $4.27B to $10.34B – an increase of 142.21%. In the next year, analysts predict that EBITDA will reach an unimpressive $10.68B – an increase of 3.37%. For the next nine years, the forecast is for EBITDA to grow by 71.04%
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| BIIB Stock Forecast | Biogen | Outperform |
4
|
$202.54 | $287.21 | 12.32% | 24 |
| GLW Stock Forecast | Corning | Outperform |
5
|
$33.27 | $47.92 | 32.25% | 3 |
| CERN Stock Forecast | Cerner | Hold |
6
|
$94.44 | $93.31 | 0.59% | 3 |
Danaher EBIT Forecast for 2022 - 2025 - 2030
Over the last three years, Danaher's EBIT has increased by 164.37%, going from $3.09B to $8.17B. In the next year, analysts are expecting a small increase in EPS, predicting it will reach $8.30B – an increase of 1.63%. The 2030 forecast is for EBIT to reach $13.28B or grow by 62.58%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| AME Stock Forecast | AMETEK | Buy |
4
|
$118.49 | $164.02 | 32.5% | 12 |
| HOLX Stock Forecast | Hologic | Outperform |
2
|
$78.39 | $78.91 | 0.78% | 12 |
| DOV Stock Forecast | Dover | Outperform |
6
|
$130.85 | $175.77 | 29.16% | 9 |
Danaher EPS Price Prediction Forecast for 2022 - 2025 - 2030
In the last three years, Danaher's EPS has seen significant growth, surging from $4.52 to $10.05 – an increase of 122.35%. In the next year, analysts predict that EPS will jump to $10.41 – up 3.58% from the current level. Looking ahead to nine years, experts forecast that EPS will grow by 127.36%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| ERF Stock Forecast | Eurofins Scientific | Hold |
2
|
86.95€ | 0.00€ | 20.76% | 10 |
| FME Stock Forecast | Fresenius Medical Care AG & Co... | Hold |
4
|
56.30€ | 80.66€ | 16% | 11 |
| BIO Stock Forecast | Bio-Rad Laboratories | Outperform |
7
|
$518.73 | $701.33 | 34.94% | 2 |